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Hypoxia occurs in regions of solid tumours as a result of poorly
formed micro-vasculature coupled with the metabolic demand of
tumour cells close to the available blood supply; this compromises
the oxygen availability to more distant tumour cells (Brown and
Giaccia, 1994). Hypoxic regions are known to be resistant to
radiotherapy and conventional chemotherapy and this has led to
much interest in the discovery of cytotoxins that kill hypoxic
tumour cells (reviewed in Stratford and Workman, 1998). These
agents are designed to be bioreduced selectively in cells low in
oxygen to produce potent cytotoxins. Synthetic compounds with
chemotherapeutic potential as bioreductive agents are usually
based on nitroaromatic or quinone structures, e.g. nitroimidazoles
and mitosenes (indoloquinones) (Workman and Stratford, 1993;
Denny et al, 1996; Patterson and Raleigh, 1998). These agents are
cytotoxic, on reduction, due to their ability to covalently bind to
DNA that will not occur in oxygenated cells. A benzotriazene di-
N-oxide, tirapazamine, is currently the most promising bioreduc-
tive drug and is in phase II/III clinical trials. This agent can act as
a chemosensitizer and radiation enhancer due primarily to toxicity
of the free radical species formed transiently during its reduction
to the non-toxic reduction product SR4317. The toxic effect is
probably caused by direct local damage to DNA that results in
DNA strand-breaks and chromosome breaks that are difficult to
repair (Brown and Wang, 1998).
To date, therefore, bioreductive agents generate transient reac-
tive species that are entirely dependent on hypoxia to generate 
the toxic species. In contrast, we report here preclinical data on 
a new class of bioreductive agent exemplified by AQ4N (1,4-bis-
{[2-(dimethylamino-N-oxide)ethyl]amino}5,8-dihydroxyan-
thracene-9, 10-dione). This agent is a prodrug designed to be
excluded from cell nuclei (Patterson, 1993; Smith et al, 1997b)
until metabolized in hypoxic cells to give AQ4, a stable, oxygen-
insensitive metabolite (Smith et al, 1997a) (Figure 1). AQ4 is a
DNA intercalator and potent inhibitor of DNA type II topoiso-
merase (Patterson, 1993; Patterson et al, 1994; Smith et al, 1997a).
Previously we have shown that AQ4N is an effective enhancer of
the anti-tumour effect of radiation in one murine tumour model,
i.e. the T50/80 mammary carcinoma grown in BDF mice
(McKeown et al, 1995, 1996). We now report on the efficacy of
this drug in several murine models. These models were selected as
they have previously been used successfully to show the efficacy
of other bioreductive drugs when used in combination with
radiation or chemotherapeutic agents (Stratford et al, 1989;
Bremner et al, 1990; Bibby et al, 1989).
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Summary AQ4 (1,4-Bis-{[2-(dimethylamino-N-oxide)ethyl]amino}5,8-dihydroxyanthracene-9, 10-dione) is a prodrug designed to be excluded
from cell nuclei until bioreduced in hypoxic cells to AQ4, a DNA intercalator and topoisomerase II poison. Thus, AQ4N is a highly selective
bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. Five murine tumours (MAC16, MAC26, NT,
SCCVII and RIF-1) have been used to investigate the anti-tumour effects of AQ4N. In only one tumour (MAC16) was AQ4N shown to be
active as a single agent. However, when combined with methods to increase the hypoxic tumour fraction in RIF-1 (by physical clamping) and
MAC26 tumours (using hydralazine) there was a substantial enhancement in anti-tumour effect. Notably, RIF-1 tumours treated with AQ4N
(250 mg kg–1) followed 15 min later by physically occluding the blood supply to the tumour for 90 min, resulted in a 13-fold increase in growth
delay. When combined with radiation or chemotherapy, AQ4N substantially increased the effectiveness of these modalities in a range of in
vivo model systems. AQ4N potentiates the action of radiation in both a drug and radiation dose-dependent manner. Further the enhancement
observed is schedule-independent with AQ4N giving similar effects when given at any time within 16 h before or after the radiation treatment.
In combination with chemotherapy it is shown that AQ4N potentiates the activity of cyclophosphamide, cisplatin and thiotepa. Both the
chemotherapeutic drugs and AQ4N are given at doses which individually are close to their estimated maximum tolerated dose (data not
included) which provides indirect evidence that in the combination chemotherapy experiments there is some tumour selectivity in the
enhanced action of the drugs. © 2000 Cancer Research Campaign
Keywords: AQ4N; radiotherapy; bioreduction; cyclophosphamide; cisplatin; thiotepa
1984
Received 1 October 1999
Revised 11 February 2000
Accepted 17 February 2000
Correspondence to: LH Patterson, The School of Pharmacy, University of
London, 29/39 Brunswick Square, London WC1N 1AX, UK
British Journal of Cancer (2000) 82(12), 1984–1990
© 2000 Cancer Research Campaign
doi: 10.1054/ bjoc.2000.1163, available online at http://www.idealibrary.com on MATERIALS AND METHODS
Materials
AQ4N and 1,4-bis-{[2-(dimethylamino)ethyl]amino}5,8-dihy-
droxy-anthracene-9,10-dione (AQ4) were synthesized as
described previously (Patterson et al, 1994). Cisplatin, cyclophos-
phamide, thiotepa and hydralazine were obtained from commer-
cial sources. Materials for cell culture were from Flow Labs
(Irvine, UK) and all other chemicals were used as purchased from
Sigma (Poole, Dorset, UK).
Murine tumour models
MAC 16, MAC26, RIF-1, NT and SCCV11 tumour-bearing
animals
Pure strain NMRI male mice, aged 6–8 weeks were used for exper-
iments with MAC16 and MAC26 tumours (Double and Ball,
1975; Bibby et al, 1987). Male C3H mice (8–12 weeks) were used
for experiments using the RIF-1 and SCCVII tumours. NT
tumours were grown in male CBA mice (Denekamp and Harris,
1975). RIF-1 and SCCVII tumours were maintained in mice by in
vivo–in vitro passage as described previously by Twentyman et
al (1980). Tumours were passaged using tumour brei from a donor
mouse or by implantation of fragments. Tumours for experiments
were implanted subcutaneously in the mid dorsal region of the
back. All animal procedures were carried out under project
licences issued by the Home Office, London, and UKCCCR
guidelines (Workman et al, 1988) for the use of animals in experi-
ments were adhered to throughout.
Tumour systems and treatments
Radiation treatments To allow local irradiation 
of tumours, unanaesthetized mice were gently restrained in
polyvinyl jigs with lead shielding and a cut-away section over the
tumour. Irradiations were done with 250 kV X-rays as described
by Stratford et al (1989). In most experiments, single high doses of
radiation were used (20 Gy for the SCCVII tumour; 25 Gy for the
RIF-1 tumour, 12 Gy for the NT tumour). These doses were
chosen to kill most of the oxic cells in these tumours, thereby
creating tumours which contained predominantly radio-resistant
hypoxic cells. This mode of treatment should reveal the
cytotoxicity of bioreductive drugs selectively toxic to hypoxic
cells when injected into mice after local irradiation of the tumours.
Drug treatments AQ4N was usually given at its maxi-
mum tolerated single dose (MTD) which was 200–250 mg kg–1
(data not shown). However, in drug combination experiments,
toxicity was observed with some chemotherapy agents, most
notably cisplatin. The doses used were therefore at or close to the
MTD of the combination as determined from pilot experiments
(data not shown). All drugs were dissolved in phosphate-buffered
saline (PBS) and administered to mice by the intraperitoneal (i.p.)
route in a 0.1 ml injection volume.
Induction of hypoxia in tumours
Two methods were employed to temporarily reduce the oxygen
status of the tumours. The first of these was physically to occlude
the blood supply to the tumours by applying a hinged, metal D-
shaped clamp around the base of the tumour to occlude the vascu-
lature for 90 min (Denekemp et al, 1983). The second was to treat
mice with 10 mg kg–1 hydralazine. Both these methods can induce
100% radiobiological hypoxia in experimental tumours (Acker
and Chaplin, 1987). In these experiments, mice were treated with
AQ4N, then 15 min later, when it is presumed that tumour levels
of drug will be high, the tumours were clamped or mice treated
with hydralazine.
Measurement of tumour response to treatment
Tumour growth delay
For NT tumours, treatment was initiated when the tumour reached
6.5–7.5 mm GMD (geometric mean of three orthogonal diameters).
Tumours were measured three times weekly and the time taken to
reach double its treatment volume was used as a measure of anti-
tumour efficacy. For RIF-1 tumours, treatment was initiated when
the tumours reached 100–200 mm3 and their growth followed until
they had reached 4 ´ the treatment volume. MAC16 and MAC26
tumours were treated when the two longest orthogonal diameters
were at least 4 and 5 mm. Tumour response was measured twice
weekly by two-dimensional caliper measurements. For RIF-1,
MAC16 and MAC26, tumour growth delay was calculated by
subtracting the mean time to grow to 4 ´ treatment volume for
control tumours from that obtained after drug exposure.
In vivo–in vitro clonogenic assay
C3H mice bearing SCCVII or RIF-1 tumours were treated upon
reaching a volume of 100–200 mm3. After 24 h tumours were
excised, minced and digested with an enzyme cocktail (6 mg
DNase, 2 mg collagenase and 2 mg pronase per 10 ml PBS) to
produce a single cell suspension. The cells were counted, diluted
as necessary, plated and incubated at 37°C in 95% air/5% carbon
dioxide for 12–14 days. Colonies were fixed, stained with 0.4%
crystal violet in methanol and scored by eye. Surviving fraction
(SF) was calculated as the number of colonies counted divided by
the number of cells plated for a given treatment, divided by the
same fraction determined for untreated control tumours.
RESULTS
Activity of AQ4N when combined with methods to
induce hypoxia
To investigate the effect of tumour hypoxia on AQ4N activity a
physical clamp and a vascular ‘steal’ agent, hydralazine were used.
Table 1 shows that AQ4N, clamping or hydralazine alone does not
significantly delay tumour growth in RIF-1 or MAC26 tumours.
However, making the tumours completely hypoxic for 
90 min, using a physical clamp, after AQ4N administration does
significantly delay tumour growth by 13-fold. Hydralazine, which
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acts as a partial pharmacological clamp also, increases the anti-
tumour effect of AQ4N in MAC26 tumours.
Activity of AQ4N in combination chemotherapy
Table 2 shows that when AQ4N (50 mg kg–1) or thiotepa 
(10 mg kg–1) alone were tested for anti-tumour efficacy against the
MAC16 tumour only a small effect (approx. 4 days delay) on
tumour growth was seen; combination of AQ4N and thiotepa at
these concentrations significantly delayed tumour growth by over
15 days (P < 0.01). Table 2 also shows that against RIF-1 tumours,
a combination of AQ4N (200 mg kg–1) and cyclophosphamide 
(50 mg kg–1) significantly delays tumour growth whereas, as single
agents, neither drug has a measurable effect. Similar results are
seen with SCCVII where clonogenic cell survival was below the
limit of detection following a combination of AQ4N (250 mg kg–1)
and cyclophosphamide (100 mg kg–1). Scheduling of drug adminis-
tration is important since tumour regression (in RIF-1) and clono-
genic cell kill (in SCCVII) is greater when cyclophosphamide is
administered 1 h prior to AQ4N compared to 1 h following AQ4N
(results not shown). In both the RIF-1 and SCCVII models the anti-
tumour effect of 8 mg kg–1 cisplatin was significantly enhanced by
combination with 100 mg kg–1 AQ4N (Table 2).
Table 1 Activity of AQ4N in combination with hypoxia inducing protocols
Treatment Tumour model Growth delaya (days) n
Hypoxia
AQ4N RIF-1 0.6±0.5 5
Clamp alone RIF-1 1.1±0.9 14
AQ4N + clamp RIF-1 14.1±1.7 8
AQ4N MAC26 0 5
AQ4N + hydralazine MAC26 5.5* 5
Hydralazine MAC26 0 5
Radation
Radiation (25 Gy) RIF-1 31.1±2.0 19
Radiation (25 Gy) + AQ4N RIF-1 59.7±4.8 5
(AQ4N immediately after radiation)
AQ4N NT 0.05±0.6 8
Radiation (12Gy) NT 3.76±2.1 8
AQ4N NT 13.76±3.8** 8
(AQ4N 30 min before radiation)
+ Radation (12 Gy)
Growth delay = time to reach 4 ´ tumour volume at treatment (treated group minus untreated group) for RIF -1
and MAC26; NT tumours were followed to 2 ´ treatment volume. AQ4N dosed i.p. MAC tumours: 50 mg kg–1;
Hydralazine (10 mg kg–1) was given 10 min after AQ4N, RIF-1 and NT tumours: 200 mg kg–1; clamping for 
90 min was carried out 15 min after AQ4N administration. See Materials and Methods for experimental details.
Mann–Whitney U-test: * P < 0.05, **P < 0.01.
Table 2 Activity of AQ4N in combination chemotherapy against murine tumours in vivo
Treatment and Drug dose Tumour Growth delaya Surviving
Time schedule (mg kg–1) (days) fractionsb
in minutes
AQ4N 50 MAC16 4.6 –
Thiotepa 10 MAC16 3.7 –
AQ4N 1 min + thiotepa 50/10 MAC1615.2** –
AQ4N 200 RIF-1 0.5 –
CPM 50 RIF-1 0.1 –
AQ4N 60 min + CPM 200/50 RIF-1 11.4*** –
AQ4N 250 SCCVII – 1.4
CPM 100 SCCVII – 0.0052
AQ4N 60 min + CPM 250/100 SCCVII – <0.00001
AQ4N 100 RIF-1 – 0.7
Cisplatin 8 RIF-1 – 0.00023
AQ4N 30 min + cisplatin 100/8 RIf-1 – <0.000001
AQ4N 100 SCCVII – 0.77
Cisplatin 8 SCCVII – 0.0004
AQ4N 30 min + cisplatin 100/8 SCCVII – <0.000001
a Time to 4 ´ initial tumour volume (treated group minus untreated group). bSurviving fraction of clonogenic cells following treatment.
All drugs were dosed i.p. See Materials and Methods for experimental details. CPM = cyclophosphamide. All results (n ³ 5 per treatment
group). Mann-Whitney U-test: *P < 0.05, **P < 0.01, ***P < 0.001.AQ4N in combination with ionizing irradiation
Previously we have shown (McKeown et al, 1995, 1996) that in
the T50/80 tumour AQ4N enhances the effect of radiation. This
was confirmed in the RIF-1 and NT tumour models (Table 1) and
led to a more detailed study in the SCCVII model (Figures 2, 3 and
4). Figure 2 shows that AQ4N considerably enhances the clono-
genic cell kill produced by a single dose of ionizing radiation 
(20 Gy) over a range of AQ4N concentrations (100–250 mg kg–1).
In fact, AQ4N doses greater than 200 mg kg–1 in combination with
ionizing radiation were so effective that the number of surviving
clonogenic cells was below the limit of detection. At this dose of
drug alone there was little, if any, measurable killing of tumour
cells.
We also investigated the effect of a range of radiation doses
(0–30 Gy) immediately followed by a single dose of AQ4N 
(250 mg kg–1) in C3H mice bearing SCCVII tumours (Figure 3).
There was a marked decrease in clonogenic cell survival as
compared to irradiation alone especially at radiation doses above
10 Gy. This will be because, at doses of 10 Gy and below, the
response of the tumour will be dominated by the aerobic popula-
tion of tumour cells, i.e. killing of the radiation-resistant hypoxic
cells will only be revealed with single doses of radiation > 10 Gy.
Since the level of tumour cell killing following 15 Gy plus AQ4N
is only seen when radiation alone is given at 30 Gy, we can calcu-
late a dose modification of 2.0 at this level of cell kill. The effect of
administering AQ4N at various times before or after irradiation of
SCCVII tumour-bearing mice was subsequently investigated (see
Figure 4). This shows that i.p. injection of AQ4N (250 mg kg–1) up
to 16 h before irradiation or up to 16 h following irradiation (20
Gy) produced a substantial increase in cell kill when these inter-
vals were increased to 24 h the potentiating effect is lost.
DISCUSSION
The rationale underlying the development of AQ4N was to design
a drug with potential for targeting DNA and DNA associated
enzymes, but which was not active until metabolized in hypoxic
tumour cells. The DNA affinity of several clinically useful agents,
including the anthracyclines and mitoxantrone, is associated with a
planar, electron-deficient chromophore bearing cationic amino
side arm(s). It was proposed that an N-oxide of a tertiary aliphatic
amine is electrically neutral and thus will exhibit a markedly
decreased DNA binding affinity compared to the reduced cationic
tertiary amine (Patterson, 1993). In fact previous studies have
shown that AQ4 has excellent DNA binding affinity (Patterson et
al, 1994) and is a DNA type II topoisomerase inhibitor (Smith et
al, 1997a). In contrast AQ4N had a equilibrium binding to DNA
which was too low to measure and AQ4N exhibited a 50-fold
decrease in topoisomerase II inhibitory activity as compared to
AQ4. AQ4N, in combination with hypoxia was a very poor cyto-
toxin against rodent and human cell lines whilst its reduction
product, AQ4 is a potent cytotoxic agent (Smith et al, 1997a). This
was confirmed in several other cell lines (Wilson et al, 1996).
Previously using the T50/80 murine tumour model in vivo we
have observed potent anti-tumour activity of AQ4N when used in
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Figure 2 The effect on surviving fraction of SCCVII tumours of various
doses of AQ4N after 20 Gy of X-radiation. C3H mice bearing the SCCVII
tumour were treated (five per group) with a range of AQ4N doses 30 min
after exposure to 20 Gy X-radiation. Mice were sacrificed 24 h later, the
tumour excised and the number of clonogenic cells determined as described
in Materials and Methods. Results are given for individual tumours. Those
which showed no clonogenic cells within the limits of detection of the assay
are indicated with downward pointing arrows
Figure 4 The effect on surviving fraction of SCCVII tumours of dosing
AQ4N at different times before or after X-radiation. C3H mice bearing the
SCCVII tumour (at least three animals per treatment group) were irradiated
with 20 Gy X-radiation. They were also administered with a single i.p. dose of
AQ4N (250 mg kg–1) at known times intervals up to 24 h before (o) or after
radiation (t t). Mice were sacrificed 24 h after each dosing interval, the tumour
excised and the number of clonogenic cells determined as described in
Materials and Methods. Results are given for individual tumours
Figure 3 The effect on surviving fraction of SCCVII tumours of 250 mg kg–1
of AQ4N after various doses of X-radiation. C3H mice bearing the SCCVII
tumour were treated with a range of X-radiation doses with (open circles) or
without (closed squares) 250 mg kg–1 of AQ4N. Drug was administered 
30 min after exposure to radiation. Mice were sacrificed 24 h later, the tumour
excised and the number of clonogenic cells determined as described in
Materials and Methods. Results are the means ± s.e.m. n = 5. Tumours
which showed no clongenic cells within the limits of detection of the assay
are indicated with downward pointing arrowscombination with radiation (McKeown et al, 1995, 1996). For all
bioreductive drugs to be useful clinically, tumour expression in
vivo of appropriate reductases will be an important determinant of
efficacy. Although not addressed in this study AQ4N is known to
be reductively metabolized by haem containing enzymes including
cytochrome P450s (CYPs). Specifically, AQ4N is a substrate for
the CYP3A subfamily under hypoxic conditions (Raleigh et al,
1998) and CYP3A has been measured in RIF-1 and SCCVII
tumours (Murray et al, 1998). CYP3A isoforms have been
detected in a broad spectrum of human cancers including colon
(Massaad et al, 1993; McKay et al, 1993) breast (Murray et al,
1993) and lung (Kivisto et al, 1995). Unlike tirapazamine it has
not proved possible to metabolize AQ4N in cultured tumour cells,
this is almost certainly due to the fact that cytochome P450s are
known to be down-regulated ex vivo (Patterson et al, 1998). We
have previously shown that the potential to metabolize AQ4N
disappears within 24 h of excision in the T50/80 tumour (Hejmadi
et al, 1996). The present studies were undertaken to further
examine the potential of AQ4N to enhance radiation and
chemotherapy in a number of in vivo murine tumours and hence
support its use as a hypoxia activated bioreductive agent in the
clinic.
Enhancement of AQ4N metabolism in vivo by hypoxia
Evidence that AQ4N is acting as a hypoxia-activated cytotoxin
comes from the combination of this agent with clamping or
hydralazine (Table 1). Clearly, the production of 100% hypoxia
with a tumour clamp enhances the anti-tumour effect of AQ4N
administered as a single agent and supports the contention that
AQ4N can be bioreductively activated in vivo. Enhancement of
the anti-tumour activity of bioreductive drugs with the vasoactive
agent, hydralazine, has previously been shown with RSU 1069
(Acker and Chaplin, 1987; Stratford et al, 1997; Brown et al,
1987) and mitomycin-C (Adams et al, 1989; Quinn et al, 1992). It
is known that the treatment of mice bearing the MAC26 colon
tumour with hydralazine produces 80% shut down in functional
tumour vasculature and greater than 60% reduction in tumour
blood perfusion (Quinn et al, 1992). The present results show that
hydralazine significantly enhances the anti-tumour efficacy of
AQ4N again supporting the hypothesis that it is bioreductively
activated in vivo despite poor activation in vitro. Our interpreta-
tion of the present data supports other published studies. Notably,
AQ4N was active against the mouse mammary tumour MDAH-
MCa-4 when combined with the tumour blood flow inhibitor 5, 6-
dimethylxanthenone-4-acetic acid (DMXAA) (Wilson et al,
1996). In addition, the anti-tumour effect of AQ4N in vivo was
potentiated in T50/80 tumours by combination with hypobaric
hypoxia with a dose enhancement ratio of 5.1 (McKeown et al,
1995).
Enhancement of chemotherapy by AQ4N
From the results presented in Table 2 it can clearly be seen that
AQ4N significantly enhances the effect of three standard
chemotherapy agents (cisplatin, cyclophosphamide and thiotepa).
This supports previous results that showed that AQ4N enhances
the anti-tumour effect of cyclophosphamide and cisplatin in the
T50/80 tumour (McKeown et al, 1998). The results with the RIF-1
and SCCVII model systems are consistent with the chemotherapeutic
enhancement effects of other bioreductive agents, including tira-
pazamine (Kim and Brown, 1994; Siim et al, 1997) and E09
(Bibby et al, 1993) in these tumour types. MAC16 is an unusual
model since it is poorly responsive to most conventional anti-
cancer drugs (Bibby et al, 1988). This may be in part because
MAC16 is a relatively slow growing tumour becoming necrotic as
it grows suggesting the presence of a significant level of hypoxia.
The significantly enhanced effect of thiotepa in combination with
AQ4N suggests that this approach might have particular value in
control of colon tumours.
Standard chemotherapy drugs typically target the well-perfused
and hence oxygenated tumour regions. The enhancement by
AQ4N on the anti-tumour effects of these drugs may be explained
by the existence in the hypoxic regions of AQ4 which would exert
its cytotoxicity on cells as they attempt to re-enter the cell cycle, in
response to the damage accrued by the well oxygenated cells.
Recently, AQ4N over a range of concentrations has been shown 
to enhance the anti-tumour effects of cyclophosphamide in 
T50/80 implants. In particular, the anti-tumour effect of AQ4N
(100 mg kg–1) combined with cyclophosphamide (100 mg kg–1)
was shown to be equivalent to that produced by a single 200 mg
kg–1 dose of cyclophosphamide alone, i.e. a 50% reduction in
cyclophosphamide dose (McKeown et al, 1998).
Enhancement of radiation therapy by AQ4N
Combination of AQ4N (200 mg kg–1) with ionizing radiation 
(25 Gy) slowed RIF-1 tumour growth by over 40% compared to
radiation alone (Table 1). This encouraging result was explored
more thoroughly using SCCVII implants, which showed that
AQ4N, over a range of concentrations, greatly enhanced the posi-
tive effects of radiation (20 Gy). When AQ4N and radiation are
administered at approximately the same time, a positive interac-
tion can be explained on the basis that the two modalities are cyto-
toxic to different (i.e. oxic or hypoxic) cell populations. However,
with AQ4N the observed enhancement is maintained even when
drug is administered up to 16 h before radiation in the SCCVII
tumour model (Figure 4); the stability and DNA affinity of AQ4 is
likely to explain this phenomenon (Smith et al, 1997a; 1997b).
Once produced, AQ4 will persist in the hypoxic cell fraction and
kill any cell which attempts to re-enter the cell cycle following
destruction of oxic cells by irradiation. When AQ4N was adminis-
tered up to 16 h after irradiation, an enhancement was also
observed. This suggests that formation of AQ4 in hypoxic cells
that have not yet re-oxygenated, can still prevent them from repop-
ulating the tumour. In T50/80 tumours a similar, although even
longer, positive interaction time was observed with a 50% dose-
sparing effect reported for up to 4 days before and 6 h after irradi-
ation (Hejmadi et al, 1996; McKeown et al, 1996). An enhanced
anti-tumour activity post radiation was also observed in MDAH-
Mca-4 tumours (Wilson et al, 1996). Overall this and previous
studies are consistent with AQ4N acting as a bioreductive radia-
tion enhancer. Differences in the time scales of the radiation
enhancement by AQ4N in SCCVII compared to T50/80 tumours
may be related to tumour clearance and/or host animal clearance
of compound. The ability of cells to survive in the hypoxic
compartment of tumours may also be a factor. Moore (1988) has
reported that T50/80 tumours have a particularly high hypoxic
fraction (60%) which suggests that T50/80 cells are capable of
remaining viable, when hypoxic, for some considerable time; a
1988 LH Patterson et al
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tion in this model previously observed (McKeown et al, 1995). In
contrast, SCCVII tumours are significantly better oxygenated and
have a faster doubling time than T50/80. This may explain the
shorter time of maximal interaction, i.e. 16 h versus 96 h in the
T50/80 tumor. The stable DNA-affinic agent AQ4, which is
produced in the hypoxic cells, will compromise the cells in which
it is generated for as long as they are viable. Once these cells die
and become necrotic the cells, and the associated AQ4, are no
longer capable of influencing tumour responses. This is likely to
occur in fast growing tumours (e.g. SCCVII) more quickly than
slow growing tumours especially those with a high proportion of
hypoxic cells (e.g. T50/80).
In conclusion AQ4N acts like a bioreductive drug when
combined with hypoxia, chemotherapy or radiation treatment in
vivo. The efficacy of the drug has now been shown against
MAC16, MAC 26, NT, RIF-1 and SCCVII, T50/80 (McKeown et
al, 1995, 1996) and MDAH-Mca-4 (Wilson et al, 1996). They all
support the use of AQ4N as a bioreductive agent that has little or
no intrinsic activity per se but is a very efficient enhancer of radia-
tion as well as standard chemotherapy agents such as cyclophos-
phamide, cisplatin and thiotepa. An additional benefit of this
bioreductively activated cytotoxin is the stable nature of the reduc-
tion product, AQ4, which may be capable of eliciting a bystander
cell killing effect on proximate non-hypoxic tumour regions. In
support of this confocal microscopy shows that viable cells
preloaded with AQ4, the authentic reduction product of AQ4N
liberate drug within 2 h despite the high DNA affinity of the latter
(Smith et al, 1997b).
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